Biointron Launches Comprehensive Antibody Developability Assessment Platform to

Mon, 01 Jan 0001 00:00:00 +0000

Why Has “Developability” Assessment Suddenly Become a Fiercely Contested Arena?

Simple answer: because people are scared of burning money. For biologic drugs, especially antibody therapeutics, up to 30% of late-stage clinical failures can be attributed to manufacturing and product quality issues. These problems often only surface after hundreds of millions of dollars and several years have been invested. The core value of platforms like Biointron’s lies in pushing the point of failure extremely early, using relatively minimal testing costs to avoid catastrophic late-stage losses. This is not just technical optimization; it’s financial engineering for risk management.

Over the past decade, antibody drugs have become the dominant force in the biopharmaceutical field, but their complex molecular structures present extremely high production barriers. An antibody that performs excellently in the lab may exhibit aggregation, instability, or purification difficulties during scale-up production. In traditional workflows, these “developability” screenings often occur only after a lead candidate is identified, leading to many projects being abruptly halted after preclinical or Phase I trials, with all prior investments lost.

CRO on SoloSoft

Biointron Launches Comprehensive Antibody Developability Assessment Platform to

Why Has “Developability” Assessment Suddenly Become a Fiercely Contested Arena?